Regina Salvat

Regina Salvat adds a business development perspective to the team which is central to their discussions with pharma companies in understanding potential assets ready to be spun out and building relationships with their current company exits. She focuses on therapeutics investments and has been essential to the investment team. Regina is currently a member of the board of directors for Pionyr and a board observer for Atsena.

Prior to joining Sofinnova in 2020, Regina was an Associate Director of Strategy and Corporate Development at Rubius Therapeutics. Before joining Rubius, Regina supported a range of bio-pharmaceutical companies as a Strategy Consultant at Huron Consulting Group (formerly, The Frankel Group). While in graduate school at Dartmouth, Regina studied Protein Engineering. Her work as a graduate student was later commercialized in a company, Stealth Biologics. Prior to graduate school, Regina worked as a Senior Associate Scientist of Cell Line Development within Bioprocess R&D at Pfizer.

Regina received her PhD from the Thayer School of Engineering at Dartmouth College, where she was a Clare Boothe Luce Fellow and Innovation Fellow. Regina also holds a B.S. in Biological Engineering and M.Eng. in Biomedical Engineering, from Cornell University.